Back

BET Inhibition with apabetalone restores cardiometabolic HFpEF through suppression of myocardial and systemic inflammation

30 August 2026 (15:45 - 15:57)
Organised by: Logo
Congress Presentation Part of: HFpEF and diastolic dysfunction Heart Failure ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ludovica Di Venanzio

Center for Translational and Experimental Cardiology (CTEC), Zurich (Switzerland)

4 More presentations in this session

Presentation thumbnail
Epigenetic remodeling drives autophagy dysfunction in cardiometabolic HFpEF
Doctor L. Di Venanzio (Zurich, CH)
Abstract Slides
Presentation thumbnail
Epigenetic reprogramming of lung fibroblasts drives pulmonary hypertension in obesity-related HFpEF
Doctor M. Telesca (Zurich, CH)
Abstract Slides
Presentation thumbnail
Endothelium-myocardial coupling mediated by endothelium-dependent hyperpolarization contributes to diastolic improvement with empagliflozin in heart failure with preserved ejection fraction
Doctor K. Watanabe (Sendai, JP)
Abstract Slides
Presentation thumbnail
Menopause exacerbates cardiovascular–kidney–metabolic–driven inflammatory and metabolic remodeling leading to diastolic dysfunction in a female swine model
Miss L. Zandbergen (Rotterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
HFpEF and diastolic dysfunction
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 15:45 CET
You may be interested in
thumbnail
Congress Presentation
The senolyitc drug ABT-263 reverses HFpEF-associated inflammation, endothelial inflammation and fibrosis
30 June 2021
thumbnail
Congress Presentation
Epigenetic repression by SAHA leads to cardio-protection in anthracycline-induced long-term cardiotoxicity
20 June 2025
thumbnail
Congress Presentation
BET protein inhibition rewires the vascular-fat interface in cardiometabolic disease
29 August 2025
thumbnail
Congress Presentation
Novel epigenetic mapping in cell-free DNA for detection of changes during sodium glucose cotransporter 2 inhibitors (SGLT2I) treatment in heart failure patients
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources